Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

CDS022971

Sigma-Aldrich

Lapatinib

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C29H26ClFN4O4S
Número CAS:
231277-92-2
Peso molecular:
581.06
Número MDL:
MFCD09264194
Código UNSPSC:
12352200
ID de substância PubChem:
329796232

descrição

AldrichCPR

Formulário

solid

cadeia de caracteres SMILES

CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O

InChI

1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

chave InChI

BCFGMOOMADDAQU-UHFFFAOYSA-N

Informações sobre genes

human ... EGFR(1956) , ERBB2(2064)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

Lapatinib is a tyrosine kinase inhibitor, targeting both the epidermal growth factor receptors, ErbB1 and ErbB-2. In combination with trastuzumab, it is reported to show complementary mechanisms of action and synergistic antitumor activity in breast cancer.

Outras notas

Please note that Sigma-Aldrich provides this product to early discovery researchers as part of a collection of unique chemicals. Sigma-Aldrich does not collect analytical data for this product. Buyer assumes responsibility to confirm product identity and/or purity. All sales are final.

NOTWITHSTANDING ANY CONTRARY PROVISION CONTAINED IN SIGMA-ALDRICH′S STANDARD TERMS AND CONDITIONS OF SALE OR AN AGREEMENT BETWEEN SIGMA-ALDRICH AND BUYER, SIGMA-ALDRICH SELLS THIS PRODUCT "AS-IS" AND MAKES NO REPRESENTATION OR WARRANTY WHATSOEVER WITH RESPECT TO THIS PRODUCT, INCLUDING ANY (A) WARRANTY OF MERCHANTABILITY, (B) WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, OR (C) WARRANTY AGAINST INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE.

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H319,H362,H413

Classificações de perigo

Aquatic Chronic 4 - Eye Irrit. 2 - Lact.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 8

1 of 8

Axitinib ≥98% (HPLC)

Sigma-Aldrich

PZ0193

Axitinib

Bosutinib ≥98% (HPLC)

Sigma-Aldrich

PZ0192

Bosutinib

Dasatinib

Sigma-Aldrich

CDS023389

Dasatinib

Sorafenib European Pharmacopoeia (EP) Reference Standard

Y0002098

Sorafenib

PHTPP ≥98% (HPLC)

Sigma-Aldrich

SML1355

PHTPP

Crizotinib ≥98% (HPLC)

Sigma-Aldrich

PZ0191

Crizotinib

Capecitabine ≥98% (HPLC)

Sigma-Aldrich

SML0653

Capecitabine

Saquinavir mesylate ≥98% (HPLC), powder

Sigma-Aldrich

S8451

Saquinavir mesylate

Melinda Halasz et al.
Science signaling, 9(455), ra114-ra114 (2016-11-24)
Signal transduction networks are often rewired in cancer cells. Identifying these alterations will enable more effective cancer treatment. We developed a computational framework that can identify, reconstruct, and mechanistically model these rewired networks from noisy and incomplete perturbation response data
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga J, et al.
The Lancet, 379(9816), 633-640 (2012)
Sydney M Shaffer et al.
Nature, 546(7658), 431-435 (2017-06-14)
Therapies that target signalling molecules that are mutated in cancers can often have substantial short-term effects, but the emergence of resistant cancer cells is a major barrier to full cures. Resistance can result from secondary mutations, but in other cases
Tushar Piyush et al.
Cell death and differentiation, 24(11), 1937-1947 (2017-07-22)
Epidermal growth factor receptor (EGFR) is an important regulator of epithelial cell growth and survival in normal and cancerous tissues and is a principal therapeutic target for cancer treatment. EGFR is associated in epithelial cells with the heavily glycosylated transmembrane
Denis M Collins et al.
Cellular immunology, 319, 35-42 (2017-07-25)
Trastuzumab is an anti-HER2 monoclonal antibody (mAb) therapy capable of antibody-dependent cell-mediated cytotoxicity (ADCC) and used in the treatment of HER2+ breast cancer. Through interactions with FcƴR+ immune cell subsets, trastuzumab functions as a passive immunotherapy. The EGFR/HER2-targeting tyrosine kinase
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica